Next Gen Biotech

Eleftha 440mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.
Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.
Eleftha 440mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.

Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Ujvira 100mg Injection and cause undesirable side effects.

Hertraz 440mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Hertraz  440mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.

Eleftha150mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Eleftha150mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.

Priunta 440mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Priunta 440mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.

Eleftha 375mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.

Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.

Eleftha 375mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.